In this portion of the HCPLive RX Review Special Report, Albert Rizzo, MD, and James Chalmers, MBChB, PhD, discuss whether specific patient subgroups may benefit more from brensocatib, the first FDA-approved therapy for bronchiectasis as of August 2025, marketed under the name Brinsupri. Chalmers explains that the ASPEN trial broadly included most phenotypes of bronchiectasis, with the exception of cystic fibrosis, active NTM infection, allergic bronchopulmonary aspergillosis, and severe immune deficiencies—conditions where neutrophil-targeting therapy may not be effective. For the vast majority of patients, including those with idiopathic, post-infective, or autoimmune-related disease, outcomes were consistent across subgroups, underscoring the central role of neutrophilic inflammation across bronchiectasis phenotypes.
